Cargando…
Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645286/ http://dx.doi.org/10.1186/2051-1426-3-S2-P150 |
| _version_ | 1782400799541821440 |
|---|---|
| author | Ferris, Robert L Even, Caroline Haddad, Robert Tahara, Makoto Goswami, Trishna Franks, April Emeribe, Ugochi Jarkowski, Anthony Melillo, Giovanni Licitra, Lisa |
| author_facet | Ferris, Robert L Even, Caroline Haddad, Robert Tahara, Makoto Goswami, Trishna Franks, April Emeribe, Ugochi Jarkowski, Anthony Melillo, Giovanni Licitra, Lisa |
| author_sort | Ferris, Robert L |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645286 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46452862015-11-20 Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle Ferris, Robert L Even, Caroline Haddad, Robert Tahara, Makoto Goswami, Trishna Franks, April Emeribe, Ugochi Jarkowski, Anthony Melillo, Giovanni Licitra, Lisa J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645286/ http://dx.doi.org/10.1186/2051-1426-3-S2-P150 Text en Copyright © 2015 Ferris et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Ferris, Robert L Even, Caroline Haddad, Robert Tahara, Makoto Goswami, Trishna Franks, April Emeribe, Ugochi Jarkowski, Anthony Melillo, Giovanni Licitra, Lisa Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle |
| title | Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle |
| title_full | Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle |
| title_fullStr | Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle |
| title_full_unstemmed | Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle |
| title_short | Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle |
| title_sort | phase iii, randomized, open-label study of durvalumab (medi4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (soc), in recurrent or metastatic (r/m) squamous cell carcinoma of the head and neck (scchn): eagle |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645286/ http://dx.doi.org/10.1186/2051-1426-3-S2-P150 |
| work_keys_str_mv | AT ferrisrobertl phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736monotherapyordurvalumabtremelimumabversusstandardofcaresocinrecurrentormetastaticrmsquamouscellcarcinomaoftheheadandneckscchneagle AT evencaroline phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736monotherapyordurvalumabtremelimumabversusstandardofcaresocinrecurrentormetastaticrmsquamouscellcarcinomaoftheheadandneckscchneagle AT haddadrobert phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736monotherapyordurvalumabtremelimumabversusstandardofcaresocinrecurrentormetastaticrmsquamouscellcarcinomaoftheheadandneckscchneagle AT taharamakoto phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736monotherapyordurvalumabtremelimumabversusstandardofcaresocinrecurrentormetastaticrmsquamouscellcarcinomaoftheheadandneckscchneagle AT goswamitrishna phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736monotherapyordurvalumabtremelimumabversusstandardofcaresocinrecurrentormetastaticrmsquamouscellcarcinomaoftheheadandneckscchneagle AT franksapril phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736monotherapyordurvalumabtremelimumabversusstandardofcaresocinrecurrentormetastaticrmsquamouscellcarcinomaoftheheadandneckscchneagle AT emeribeugochi phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736monotherapyordurvalumabtremelimumabversusstandardofcaresocinrecurrentormetastaticrmsquamouscellcarcinomaoftheheadandneckscchneagle AT jarkowskianthony phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736monotherapyordurvalumabtremelimumabversusstandardofcaresocinrecurrentormetastaticrmsquamouscellcarcinomaoftheheadandneckscchneagle AT melillogiovanni phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736monotherapyordurvalumabtremelimumabversusstandardofcaresocinrecurrentormetastaticrmsquamouscellcarcinomaoftheheadandneckscchneagle AT licitralisa phaseiiirandomizedopenlabelstudyofdurvalumabmedi4736monotherapyordurvalumabtremelimumabversusstandardofcaresocinrecurrentormetastaticrmsquamouscellcarcinomaoftheheadandneckscchneagle |